CRISPR (CRSP) GC James R. Kasinger Exercises Options, Sells Shares

What Happened

• James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics (CRSP), exercised options to acquire 10,400 common shares at $13.62 per share (total exercise cost $141,648) and simultaneously sold those 10,400 shares in the open market for aggregate proceeds of $626,460 (weighted average sale price $60.24) on September 22, 2026. The filing also shows the related derivative (the option) was disposed/cancelled in connection with the exercise.

Key Details

• Transaction date: September 22, 2026. Form 4 filed September 24, 2026 (timely).
• Exercise: 10,400 shares acquired at $13.62 each — total $141,648.
• Sale: 10,400 shares sold in multiple trades, weighted average price $60.24, total proceeds $626,460; sale prices ranged from $60.00 to $60.65.
• Derivative disposition: 10,400 option units reported as disposed at $0.00 (reflects cancellation/settlement of the option upon exercise).
• Footnotes: 476 of the shares were acquired under the 2026 Employee Stock Purchase Plan (ESPP). Sales were made under a Rule 10b5-1 trading plan adopted May 6, 2026. The underlying option was originally granted May 31, 2017 (vesting schedule noted in footnote).
• Shares owned after transaction: not specified in the provided filing excerpt.

Context

• This was effectively a cash exercise of options followed by an immediate open-market sale (a common pattern often used to cover exercise cost/taxes or diversify). The sale was executed under a pre-established 10b5-1 plan, which is intended to provide an objective framework for insider sales. All information above is factual from the Form 4; it does not indicate the insider’s motivation.